|
Live attenuated oral Salmonella platform for effective T- and B-cell targeting of PD-L1. |
| |
|
|
Stock and Other Ownership Interests - VAXIMM |
Travel, Accommodations, Expenses - VAXIMM |
| |
|
No Relationships to Disclose |
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
|
Stock and Other Ownership Interests - Cellvax |
| |
|
|
|
Stock and Other Ownership Interests - VAXIMM |
Consulting or Advisory Role - BB Biotech Ventures |
Travel, Accommodations, Expenses - VAXIMM |
| |
|
|
Stock and Other Ownership Interests - VAXIMM |
| |
|
|
|
Stock and Other Ownership Interests - VAXIMM |
Travel, Accommodations, Expenses - VAXIMM |
| |
|
No Relationships to Disclose |
| |
|
Honoraria - Bristol-Myers Squibb; Roche; VAXIMM |
Consulting or Advisory Role - Bristol-Myers Squibb; Roche |
|
Research Funding - VAXIMM |
Patents, Royalties, Other Intellectual Property - Bayer |
Travel, Accommodations, Expenses - Boehringer Ingelheim; Roche |
| |
|
|
|
Stock and Other Ownership Interests - VAXIMM |
Patents, Royalties, Other Intellectual Property - VAXIMM |
Travel, Accommodations, Expenses - VAXIMM |